Next Article in Journal
Lost in Translation: Ambiguity in Nerve Sheath Tumor Nomenclature and Its Resultant Treatment Effect
Next Article in Special Issue
Immunotherapy and Immune Evasion in Prostate Cancer
Previous Article in Journal
Metabolomic Dynamic Analysis of Hypoxia in MDA-MB-231 and the Comparison with Inferred Metabolites from Transcriptomics Data
Previous Article in Special Issue
Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer
Open AccessArticle

The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T

1
Division of Pharmacy, MD Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX 77030, USA
2
Division of Biostatistics, MD Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX 77030, USA
3
Division of Genitourinary Medical Oncology, MD Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
Cancers 2013, 5(2), 511-518; https://doi.org/10.3390/cancers5020511
Received: 19 March 2013 / Revised: 19 March 2013 / Accepted: 22 April 2013 / Published: 6 May 2013
(This article belongs to the Special Issue Immune Responses to Human Prostate Cancer)
Sipuleucel-T is an immunotherapy indicated for the treatment of metastatic prostate cancer. It offers a new mechanism to treat prostate cancer without the side effects of hormone therapies and chemotherapies. In previous studies sipuleucel-T did not delay disease progression, but demonstrated an overall survival benefit compared to placebo. While clinical trials have evaluated the effects of sipuleucel-T on overall survival and progression, more studies are needed to evaluate its effectiveness and role in the management of prostate cancer. The objective of this study is to identify the incidence and possible predictors for disease progression in patients receiving sipuleucel-T. A retrospective review of patients who received sipuleucel-T between 1 September 2010 and 11 October 2011 was conducted (n = 36). Patients who changed therapy or died within 120 days were classified as experiencing rapid progression. Potential predictors of rapid progression were examined using logistic regression. Seven patients met criteria for rapid progression. Progression occurred in 72.2% of all patients. The median days to progression was 158. No significant predictors of rapid progression were identified. Currently no predictors have been found to be associated with rapid progression in prostate cancer patients on sipuleucel-T. View Full-Text
Keywords: prostate cancer; sipuleucel-T; immunotherapy; progression; metastasis prostate cancer; sipuleucel-T; immunotherapy; progression; metastasis
Show Figures

Figure 1

MDPI and ACS Style

Ng, L.; Heck, W.; Lavsa, S.; Crowther, D.; Atkinson, B.; Xiao, L.; Araujo, J. The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T. Cancers 2013, 5, 511-518.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop